Cantor Fitzgerald raises Zevra Therapeutics stock price target to $29 on NPC drug progress

Cantor Fitzgerald raised its price target on Zevra Therapeutics (ZVRA) to $29 from $25, maintaining an Overweight rating, citing significant progress in its arimoclomol program for Niemann Pick Disease Type C (NPC) and the substantial European market opportunity. This follows the company's Q1 2025 revenue of $20.4 million, which exceeded forecasts primarily from its MyPlifa product, despite a net loss of $3.1 million. H.C. Wainwright also initiated coverage with a Buy rating, emphasizing Zevra's successful transition to a commercial-stage rare disease entity and the stock's potential undervaluation, reflecting strong growth prospects.

Analysis

Zevra Therapeutics (ZVRA) is experiencing significant positive momentum, driven by favorable analyst actions and fundamental progress in its rare disease pipeline. Cantor Fitzgerald has raised its price target to $29.00 from $25.00, maintaining an Overweight rating, while H.C. Wainwright initiated coverage with a Buy rating. This bullish sentiment is underpinned by key developments for its Niemann Pick Disease Type C (NPC) treatment, arimoclomol (Miplyffa), including a new mechanistic study expected to boost physician confidence and progress toward European regulatory approval. Financially, the company demonstrated strong commercial execution in Q1 2025, reporting revenue of $20.4 million, which surpassed the $16.02 million forecast, although it still incurred a net loss of $3.1 million. Analysts view the stock as undervalued, with the European market opportunity for Miplyffa identified as a primary growth catalyst that could potentially rival the U.S. market in size. The stock's recent performance, doubling over the past year and rising 19% in the last week, reflects growing investor confidence in this commercial and regulatory strategy.

Key Decisions for Investors

• Given the significant disconnect between the current price of $11.56 and analyst targets like Cantor Fitzgerald's $29.00, investors should evaluate the stock's potential for substantial upside, which is predicated on the successful commercialization of Miplyffa.
• The primary catalyst to monitor is the European regulatory submission and potential approval for Miplyffa, as this event is central to the growth and undervaluation thesis presented by analysts.
• While top-line growth is strong, investors must balance this against the company's current unprofitability, highlighted by its Q1 net loss, and should assess the timeline and execution risks associated with achieving sustained profitability.